2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

By C. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. Casey, M. Drazner, G. Fonarow, S. Geraci, T. Horwich, J. Januzzi and 14 more. Circulation, 2013

3,726 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes – Mechanisms, Management, and Clinical Considerations (2016, neutral): “benefits and are recommended for the treatment of chronic heart failure.(422,465) In chronic heart failure trials, up to 30% of participants generally have comorbid diabetes mellitus,(466) and”
2024 ESC Guidelines for the management of elevated blood pressure and hypertension. (2024, neutral): “158,159 The same is true for heart failure with reduced ejection fraction (HFrEF).”
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “Atorvastatin (40†)–80 mg Rosuvastatin 20 (40) mg Atorvastatin 10 (20) mg Rosuvastatin (5) 10 mg Simvastatin 20–40 mg‡ Pravastatin 40 (80) mg Lovastatin 40 mg Fluvastatin XL 80 mg Fluvastatin 40 mg bid Pitavastatin 2–4 mg Simvastatin 10 mg Pravastatin 10–20 mg Lovastatin 20 mg Fluvastatin 20–40 mg Pi”